Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 24, 2017

Study Completion Date

May 24, 2017

Conditions
Neurocognitive Improvement
Interventions
DRUG

Citicoline

Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.

OTHER

Microcrystalline Cellulose

Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.

Trial Locations (1)

84108

The Brain Institute, University of Utah, Salt Lake City

All Listed Sponsors
lead

Deborah Yurgelun-Todd

OTHER

NCT01582113 - Cognizin Citicoline Dosing in a Healthy Adolescent Male Population | Biotech Hunter | Biotech Hunter